Literature DB >> 7687150

Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism.

M Narayan1, S Srinath, G M Anderson, D B Meundi.   

Abstract

Cerebrospinal fluid (CSF) concentrations of the serotonin and dopamine metabolites, 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA), respectively, were measured in a group of 17 children with Autistic Disorder (DSM-III-R). The group means observed for 5HIAA (135 +/- 91 nmol/L) and HVA (502 +/- 324 nmol/L) in the autistic children were not significantly different from those seen in the control group of 15 nonneurologically impaired children (5HIAA, 122 +/- 120 nmol/L; HVA 401 +/- 378 nmol/L). These data suggest that consistent, marked alterations in central serotonin and dopamine turnover are not present in the autistic subjects studied. Although studies to date have found little or no alteration in CSF 5-HIAA in autism, the various reports of CSF HVA are not entirely congruent. Although this study is consistent with most previous studies in not finding a group difference in CSF HVA, the possibility of increased CSF HVA in autism cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687150     DOI: 10.1016/0006-3223(93)90102-j

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  9 in total

Review 1.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  Decreased cerebral spinal fluid neurotransmitter levels in Smith-Lemli-Opitz syndrome.

Authors:  S E Sparks; C A Wassif; H Goodwin; S K Conley; D C Lanham; L E Kratz; K Hyland; A Gropman; E Tierney; F D Porter
Journal:  J Inherit Metab Dis       Date:  2014-02-06       Impact factor: 4.982

Review 3.  Etiology of infantile autism: a review of recent advances in genetic and neurobiological research.

Authors:  G Trottier; L Srivastava; C D Walker
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

Review 4.  Medication treatment in subjects with autistic spectrum disorders.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

5.  Comparative evaluation of 5-HIAA (5-hydroxy indoleacetic acid) and HVA (homovanillic acid) in infantile hydrocephalus.

Authors:  S C Gopal; A Pandey; I Das; A N Gangopadhyay; V D Upadhyaya; J P N Chansuria; T B Singh
Journal:  Childs Nerv Syst       Date:  2007-12-12       Impact factor: 1.475

Review 6.  Antipsychotics in the treatment of autism.

Authors:  David J Posey; Kimberly A Stigler; Craig A Erickson; Christopher J McDougle
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

7.  Association of ADHD, tics, and anxiety with dopamine transporter (DAT1) genotype in autism spectrum disorder.

Authors:  Kenneth D Gadow; Jasmin Roohi; Carla J DeVincent; Eli Hatchwell
Journal:  J Child Psychol Psychiatry       Date:  2008-12       Impact factor: 8.982

8.  A lack of association between hyperserotonemia and the increased frequency of serum anti-myelin basic protein auto-antibodies in autistic children.

Authors:  Gehan Ahmed Mostafa; Laila Yousef Al-Ayadhi
Journal:  J Neuroinflammation       Date:  2011-06-22       Impact factor: 8.322

9.  Association of social and cognitive impairment and biomarkers in autism spectrum disorders.

Authors:  Altaf Alabdali; Laila Al-Ayadhi; Afaf El-Ansary
Journal:  J Neuroinflammation       Date:  2014-01-08       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.